{
    "paper_id": "PMC7192114",
    "metadata": {
        "title": "Emerging key laboratory tests for patients with COVID-19",
        "authors": [
            {
                "first": "Peter",
                "middle": [
                    "A."
                ],
                "last": "Kavsak",
                "suffix": "",
                "email": "kavaskp@mcmaster.ca",
                "affiliation": {}
            },
            {
                "first": "Kerstin",
                "middle": [],
                "last": "de Wit",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Andrew",
                "middle": [],
                "last": "Worster",
                "suffix": "",
                "email": null,
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "The three CBC findings of poor prognosis are: leukocytosis, thrombocytopenia, and lymphocytopenia.[1], [2], [3] Lymphocytopenia occurs across populations regardless of co-infection. Whether poor prognosis is associated with lymphocytopenia below the reference interval or absolute count is unclear.",
            "cite_spans": [
                {
                    "start": 98,
                    "end": 101,
                    "mention": "[1]",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 103,
                    "end": 106,
                    "mention": "[2]",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 108,
                    "end": 111,
                    "mention": "[3]",
                    "ref_id": "BIBREF2"
                }
            ],
            "section": "Complete blood count (CBC) with differential",
            "ref_spans": []
        },
        {
            "text": "COVID-19 patients have high concentrations of the acute phase response proteins (i.e., c-reactive protein [CRP] and ferritin) and inflammatory biomarkers (i.e., cytokines such as Interleukin-6; IL-6) at admission.[1], [2] CRP is more widely available, and is a sensitive biomarker of inflammation and tissue damage that is increased at admission and during hospitalization.[2], [4]\n",
            "cite_spans": [
                {
                    "start": 213,
                    "end": 216,
                    "mention": "[1]",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 218,
                    "end": 221,
                    "mention": "[2]",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 373,
                    "end": 376,
                    "mention": "[2]",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 378,
                    "end": 381,
                    "mention": "[4]",
                    "ref_id": "BIBREF3"
                }
            ],
            "section": "Acute phase response and inflammatory biomarkers",
            "ref_spans": []
        },
        {
            "text": "Kidney injury prevalence (via creatinine measurement) at admission is unknown but 11-15% of hospitalized COVID-19 patients may have acute kidney injury.[1], [2] Alanine aminotransferase (ALT) elevations at admission range from 22% to 32% and cardiac injury (via cardiac troponin measurement) has been reported to range from 15% to 44%.[1], [2], [3] Other liver biomarkers are reported to be increased; however, ALT is more specific for liver injury and is also less affected by pre-analytical factors such as hemolysis.",
            "cite_spans": [
                {
                    "start": 152,
                    "end": 155,
                    "mention": "[1]",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 157,
                    "end": 160,
                    "mention": "[2]",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 335,
                    "end": 338,
                    "mention": "[1]",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 340,
                    "end": 343,
                    "mention": "[2]",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 345,
                    "end": 348,
                    "mention": "[3]",
                    "ref_id": "BIBREF2"
                }
            ],
            "section": "Kidney, liver and cardiac injury",
            "ref_spans": []
        },
        {
            "text": "Following recovery and 7-days post-convalescent plasma transfusion, CRP levels decreased by >10-fold, which was more pronounced than IL-6 and procalcitonin (\u223c 2-fold difference).4 Procalcitonin is a useful indicator for bacterial infections, though not all patients with COVID-19 have bacterial co-infections.[3], [4]\n",
            "cite_spans": [
                {
                    "start": 178,
                    "end": 179,
                    "mention": "4",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 309,
                    "end": 312,
                    "mention": "[3]",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 314,
                    "end": 317,
                    "mention": "[4]",
                    "ref_id": "BIBREF3"
                }
            ],
            "section": "Tests which may indicate improvement",
            "ref_spans": []
        },
        {
            "text": "D-dimer and high-sensitivity cardiac troponin can also identify COVID-19 patients who are at low- and high-risk for death.[1], [2], [5] D-dimer is used in decision making for disseminated intravascular coagulation, deep vein thrombosis or pulmonary embolism and is given a high priority of testing in patients with COVID-19.5 While for high-sensitivity cardiac troponin, normal or low concentrations (typically below 5 ng/L, but cutoffs are assay specific) identifies patients at low-risk for cardiovascular outcomes and death in many different populations, including COVID-19 patients.[1], [2]\n",
            "cite_spans": [
                {
                    "start": 122,
                    "end": 125,
                    "mention": "[1]",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 127,
                    "end": 130,
                    "mention": "[2]",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 132,
                    "end": 135,
                    "mention": "[5]",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 324,
                    "end": 325,
                    "mention": "5",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 586,
                    "end": 589,
                    "mention": "[1]",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 591,
                    "end": 594,
                    "mention": "[2]",
                    "ref_id": "BIBREF1"
                }
            ],
            "section": "Prognostic biomarkers",
            "ref_spans": []
        },
        {
            "text": "Two clinical scores that may also identify patients with COVID-19 at low- and high-risk for death are the sequential organ failure assessment (SOFA) score used in sepsis and the confusion, urea, respiratory rate, blood pressure, and age \u2265 65 years (CURB-65) score in the assessment of severity in patients with community acquired pneumonia. Both clinical scores require laboratory testing.",
            "cite_spans": [],
            "section": "Clinical Scores",
            "ref_spans": []
        },
        {
            "text": "Conflict of Interest Disclosures: Dr. Kavsak has received grants/reagents/consultant/advisor/ honoraria from serval diagnostic companies, including Abbott Laboratories, Abbott Point of Care, Beckman Coulter, Ortho Clinical Diagnostics, Randox Laboratories, Roche Diagnostics and Siemens Healthcare Diagnostics. McMaster University has filed patents with Dr. Kavsak listed as an inventor in the acute cardiovascular biomarker field. Dr de Wit has received a research grant from Bayer.",
            "cite_spans": [],
            "section": "Clinical Scores",
            "ref_spans": []
        }
    ],
    "ref_entries": {
        "TABREF0": {
            "text": "Table 1: Emerging key laboratory tests for patients with COVID-19\n",
            "type": "table"
        }
    },
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study",
            "authors": [
                {
                    "first": "F.",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "T.",
                    "middle": [],
                    "last": "Yu",
                    "suffix": ""
                },
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Du",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "395",
            "issn": "",
            "pages": "1054-1062",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF1": {
            "title": "Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study",
            "authors": [
                {
                    "first": "T.",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "D.",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "BMJ",
            "volume": "368",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF2": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF3": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF4": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        }
    }
}